Market capitalization | $81.50m |
Enterprise Value | $49.48m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 4,948.00 |
P/S ratio (TTM) P/S ratio | 8,150.00 |
P/B ratio (TTM) P/B ratio | 2.46 |
Revenue growth (TTM) Revenue growth | -96.64% |
Revenue (TTM) Revenue | $10.00k |
EBIT (operating result TTM) EBIT | $-28.95m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
5 Analysts have issued a Genelux forecast:
5 Analysts have issued a Genelux forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.01 0.01 |
96%
96%
|
|
Gross Profit | -0.87 -0.87 |
6%
6%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -29 -29 |
43%
43%
|
Net Profit | -28 -28 |
11%
11%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.
Head office | United States |
CEO | Thomas Zindrick |
Employees | 23 |
Founded | 2001 |
Website | www.genelux.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.